These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33901503)

  • 1. Targeting the dysfunction of glutamate receptors for the development of novel antidepressants.
    Xia CY; He J; Du LD; Yan Y; Lian WW; Xu JK; Zhang WK
    Pharmacol Ther; 2021 Oct; 226():107875. PubMed ID: 33901503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression.
    Wang YT; Wang XL; Feng ST; Chen NH; Wang ZZ; Zhang Y
    Pharmacol Res; 2021 Sep; 171():105761. PubMed ID: 34242798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
    Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Exploring N-Methyl-D-Aspartate (NMDA) as a Future Perspective Target in Depression.
    Bhatia NY; Ved HS; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2022; 21(10):1004-1016. PubMed ID: 35352638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sigma-1 receptor: A potential target for the development of antidepressants.
    Wang YM; Xia CY; Jia HM; He J; Lian WW; Yan Y; Wang WP; Zhang WK; Xu JK
    Neurochem Int; 2022 Oct; 159():105390. PubMed ID: 35810915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GluN2A: A Promising Target for Developing Novel Antidepressants.
    Wang G; Qi W; Liu QH; Guan W
    Int J Neuropsychopharmacol; 2024 Sep; 27(9):. PubMed ID: 39185814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT
    Fukumoto K; Fogaça MV; Liu RJ; Duman CH; Li XY; Chaki S; Duman RS
    Neuropsychopharmacology; 2020 Sep; 45(10):1725-1734. PubMed ID: 32396921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate-based antidepressants: 20 years on.
    Skolnick P; Popik P; Trullas R
    Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.